AmericasENPublic regulatory overview
Mexico
Market Overview Population: Approximately 130 million (2024), Latin America's secondlargest economy Healthcare system: Layered structure — IMSS (Instituto Mexicano del Seguro Socia...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAStrong benefitFDA evidence can materially improve review confidence and may support verification, abridged, or reliance-style pathways.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRStrong benefitCE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditIndirect QMS signalMDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingSupportive evidenceNMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: Mexico
- Product line: Medical devices
- Regulator / source: Regulatory maturity: Moderate to high — the COFEPRIS framework is relatively mature, though review capacity is constrained by resources. Regulations are broadly aligned with the US/EU approach (referencing FDA classification). Government transitions have a significant impact on COFEPRIS policy direction
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
- Key fees: Market characteristics: The medical device market is valued at approximately USD 4–5 billion per year, with a high import dependency (approximately 90%, primarily from the United States). The USMCA (United States-Mexico-Canada Agreement) provides tariff advantages for US-origin devices. Local manufacturing is concentrated in Baja California, a major medical device export manufacturing hub
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Population: Approximately 130 million (2024), Latin America's second-largest economy
- Healthcare system: Layered structure — IMSS (Instituto Mexicano del Seguro Social, covering formal-sector workers), ISSSTE (government employees), and Pemex/military medical systems; IMSS-Bienestar (formerly Insabi) covers the uninsured population; the private sector is growing rapidly
- Market characteristics: The medical device market is valued at approximately USD 4–5 billion per year, with a high import dependency (approximately 90%, primarily from the United States). The USMCA (United States-Mexico-Canada Agreement) provides tariff advantages for US-origin devices. Local manufacturing is concentrated in Baja California, a major medical device export manufacturing hub
- Regulatory maturity: Moderate to high — the COFEPRIS framework is relatively mature, though review capacity is constrained by resources. Regulations are broadly aligned with the US/EU approach (referencing FDA classification). Government transitions have a significant impact on COFEPRIS policy direction
Regulatory Authority
- Primary authority: COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), under the SSA (Secretaría de Salud)
- Official portal: https://www.gob.mx/cofepris; electronic filing: SINARETT (Sistema Nacional de Registros de la SSA); https://tramites.cofepris.gob.mx
- Key regulations:
- Ley General de Salud (General Health Law)
- Reglamento de Insumos para la Salud (Health Supplies Regulation, RIS)
- NOM-137-SSA1-2008 (requirements for medical devices and IVDs)
- NOM-240-SSA1-2012 (post-market surveillance)
- NOM series standards (technical requirements by product category)
- Acuerdo de clasificación de dispositivos médicos (device classification agreement)
Device Classification
| Local Classification | Risk Level | EU/FDA Equivalent | Description |
|---|---|---|---|
| Clase I | Low risk | EU Class I / FDA Class I | Some products are exempt from registration or follow a simplified notification-only pathway |
| Clase II | Moderate risk | EU Class IIa-IIb / FDA Class II | Registro Sanitario, standard pathway |
| Clase III | High risk | EU Class III / FDA Class III | Registro Sanitario, most stringent review; complete technical documentation required |
Note: Classification is based on risk level and invasiveness; the FDA classification code cross-reference table may be used as a guide. COFEPRIS has published an official classification directory. IVDs follow separate classification rules.
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.